View Larger
Branimir I. Sikic, M. D.
Key Documents
Contact Information
-
Clinical Offices
Medical Oncology 875 Blake Wilbur Dr. Clinic E MC 5820 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 725-9113
- Academic Offices
Personal Information Email Tel (650) 725-6427Alternate Contact Carla Edwards Administrative Assistant Email Tel Work 650-723-5290Not for medical emergencies or patient use
Bio
Clinical Focus
- Cancer> Sarcoma
- Medical Oncology
- New Drug Studies
Administrative Appointments
- Associate Director, Stanford Cancer Center (2009 - present)
- Co-Director, Stanford Center for Clinical and Translational Education and Research, Stanford University (2008 - present)
- Director, Clinical and Translational Research Unit, Stanford University (2008 - present)
- Scientific Program Committee Chair, American Society of Clinical Oncology (2005 - 2006)
Honors and Awards
- Presidential Medal for Science and Medicine, Government of Croatia (2010)
- Statesman Award, American Society of Clinical Oncology (2010)
- John H. Blaffer Visiting Professor, M.D. Anderson Cancer Center (2003)
- Best Doctors in America, "Best Doctors" annual survey (2002-13)
- Oncology Teaching Award, Oncology Division, Stanford (2000)
- Plenary lecturer in drug resistanc e, Netherlands Cancer Institute (1999)
Professional Education
| Fellowship: | Georgetown University Hospital DC (1979) |
| Residency: | Georgetown University Hospital DC (1975) |
| Board Recertification: | Medical Oncology, American Board of Internal Medicine (2010) |
| Board Certification: | Medical Oncology, American Board of Internal Medicine (1979) |
| Fellowship: | National Cancer Institute MD (1978) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (1975) |
Community and International Work
- Central European Oncology Congress, Opatija, Croatia
Research & Scholarship
Current Research and Scholarly Interests
Our goals are to understand mechanisms of drug resistance in cancer cells and to develop more effective therapies. Current research ranges from biochemical and molecular studies in cellular models to Phase I, II and III clinical trials of new inhibitors of drug resistance and novel therapies such as multi-targeted tyrosine kinase inhibitors and activators of TRAIL signaling. We are developing approaches to personalized therapies of ovarian cancer using biomarkers to select individualized treatments for patients.
Laboratory projects include studies of the multidrug transporter P-glycoprotein, regulation of the MDR1 gene, the role of beta tubulin gene expression in resistance to taxanes and vinca alkaloids, and the use of gene expression profiling in discovering molecular and genetic determinants of outcomes in cancer treatment in various cancers, particularly ovarian, colorectal, and acute myeloid leukemias.
Clinical investigations include the prognostic significance of resistance gene expression in cancers, pharmacokinetic consequences of MDR modulation, development of new modulators of drug resistance, and new targeted drugs, including kinase inhibitors and inhibitors of apoptosis. We are performing pharmacogenetic and pharmacogenomic studies to investigate determinants of response and toxicities in these patients.
Clinical Trials
- Not Recruiting Phase 1 Trial of Oral Ixabepilone
- Recruiting Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia
- Not Recruiting A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
- Recruiting A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
- Not Recruiting Safety Study of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Teaching
Courses
2013-14
- Directed Reading in Cancer Biology
CBIO 299 (Aut, Win, Spr, Sum) - Directed Reading in Medicine
MED 299 (Aut, Win, Spr, Sum) - Early Clinical Experience in Medicine
MED 280 (Aut, Win, Spr, Sum) - Graduate Research
CBIO 399 (Aut, Win, Spr, Sum) - Graduate Research
MED 399 (Aut, Win, Spr, Sum) - Medical Scholars Research
MED 370 (Aut, Win, Spr, Sum) - Out-of-Department Advanced Research Laboratory in Experimental Biology
BIO 199X (Aut, Win, Spr, Sum) - Out-of-Department Graduate Research
BIO 300X (Aut, Win, Spr, Sum) - Undergraduate Research
MED 199 (Aut, Win, Spr, Sum)
Independent Studies (9)
Graduate and Fellowship Program Affiliations
Publications
Publications
- Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors INVESTIGATIONAL NEW DRUGS 2012; 30 (6): 2364-2370
- A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer INVESTIGATIONAL NEW DRUGS 2012; 30 (3): 1082-1087
- Clinical trial designs for testing biomarker-based personalized therapies CLINICAL TRIALS 2012; 9 (2): 141-154
- Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies INVESTIGATIONAL NEW DRUGS 2011; 29 (5): 971-977
- NFKBIA Deletion in Glioblastomas. NEW ENGLAND JOURNAL OF MEDICINE 2011; 364 (7): 627-637
- Expression and Silencing of the Microtubule-Associated Protein Tau in Breast Cancer Cells MOLECULAR CANCER THERAPEUTICS 2010; 9 (11): 2970-2981
Help